European Pharmaceutical Review

DECEMBER 28, 2023

In this exclusive interview, Andreas Harstrick, the Chief Medical Officer of Affimed unveils the potential of innate cell engagers for treating lymphoma. How has the treatment landscape for lymphoma evolved over the past few years?

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

European Pharmaceutical Review

SEPTEMBER 26, 2023

Resminostat (Kinselby) has been clinically proven to postpone disease progression, new data from one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to date has revealed. Findings from the RESMAIN study of the maintenance therapy could significantly change clinical practice in advanced CTCL” A 97.6

Patients 91

Patients Medical Pharmaceutical Marketing 91

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.

Pharmaceutical 40

Pharmaceutical 40

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results.

Patients 84

Patients Side effects Healthcare Healthcare 84

MedCity News

MAY 2, 2023

Johnson & Johnson is acquiring rights to two next-generation cell therapies from Cellular Biomedicines, both potential treatments for diffuse large B-cell lymphoma. One therapy is already in the clinic while the other is on track to begin human testing this year.

Biopharma 102

Biopharma Pharma 102

Pharmacy Times

SEPTEMBER 8, 2023

Correctly diagnosing specific follicular lymphomas and marginal zone lymphomas requires knowledge of the clinical context, including the site of involvement, age, and clinical presentation.

58

58

Pharmaceutical Technology

JANUARY 4, 2024

CB-010 is under clinical development by Caribou Biosciences and currently in Phase I for Follicular Lymphoma.

69

69

European Pharmaceutical Review

APRIL 20, 2023

It has been nearly 20 years since a new treatment option has become available [for] newly diagnosed with diffuse large B-cell lymphoma [in the US]” The US Food and Drug Administration (FDA) has approved Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). “It

Food and Drug Administration 95

Food and Drug Administration FDA Food Patients 95

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Marketing 95

Marketing Sales Physicians Patients 95

Pharmaceutical Technology

JUNE 27, 2022

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for its CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.

Food and Drug Administration 105

Food and Drug Administration FDA Food Safety 105

Pharmaceutical Technology

DECEMBER 21, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

Pharmaceutical 40

Pharmaceutical 40

European Pharmaceutical Review

OCTOBER 31, 2022

AbbVie has announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application (MAA) for epcoritamab, a bispecific antibody (bsAb) for adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after more than two lines of systemic therapy, offering patients a potential new therapy option.

Food and Drug Administration 88

Food and Drug Administration Medicine Food Safety 88

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

Leads 98

Leads Patients Pharmaceutical 98

Pharmaceutical Technology

APRIL 3, 2023

Eisai and the National Cancer Center have signed an agreement to partner on investigator-initiated clinical research for the anti-cancer agent, tazemetostat (Tazverik Tablets 200 mg), based on the Patient-Proposed Healthcare Services system.

Insurance 98

Insurance Government Safety Patients 98

European Pharmaceutical Review

NOVEMBER 21, 2023

BRUKINSA ® (zanubrutinib) in combination with the anti-CD20 monoclonal antibody obinutuzumab, has been approved by the European Commission (EC) to treat relapsed or refractory follicular lymphoma in individuals who have received at least two prior lines of systemic therapy.

Engineering 96

Engineering Medical Patients Medicine 96

Pharmaceutical Technology

JANUARY 8, 2024

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

52

52

Pharmaceutical Technology

JULY 7, 2023

AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Follicular Lymphoma.

75

75

Pharmaceutical Technology

JUNE 16, 2023

Roche Group member Genentech has secured approval from the US Food and Drug Administration (FDA) for its Columvi (glofitamab-gxbm) to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Columvi will be available in the US later this year.

Food and Drug Administration 59

Food and Drug Administration FDA Food Medical 59

European Pharmaceutical Review

NOVEMBER 22, 2022

The US Food and Drug Administration ( FDA ) has accepted priority review of AbbVie’s Biologics License Application of epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody (BsAb), for adults with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

FDA 88

FDA Food and Drug Administration Safety Food 88

Pharmaceutical Technology

DECEMBER 26, 2023

NVG-111 is under clinical development by NovalGen and currently in Phase I for Mantle Cell Lymphoma.

52

52

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

40

40

Pharmaceutical Technology

OCTOBER 26, 2023

NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase III for Diffuse Large B-Cell Lymphoma.

52

52

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.

40

40

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma.

52

52

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Follicular Lymphoma.

40

40

pharmaphorum

SEPTEMBER 26, 2022

Japan’s Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (ATL). Another from Jiangsu Hengrui Medicine (SHR2554) is still in early-stage clinical development.

Patients 86

Patients Medicine FDA Medical 86

Pharmaceutical Technology

MAY 16, 2023

ImmPACT Bio has received fast track designation (FTD) from the US Food and Drug Administration (FDA) for IMPT-314 to treat relapsed or refractory (R/R) aggressive B-cell lymphoma. It will also be used for the treatment of DLBCL arising from follicular lymphoma, following two or more lines of systemic therapy.

Food and Drug Administration 52

Food and Drug Administration FDA Food Patients 52

European Pharmaceutical Review

JANUARY 30, 2023

It is indicated for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. The post FDA approves first BTK inhibitor for lymphoma appeared first on European Pharmaceutical Review. This was based on response rate from the Phase I/II BRUIN study.

FDA 91

FDA Food and Drug Administration Food Safety 91

Pharmaceutical Technology

NOVEMBER 6, 2023

AWT-020 is under clinical development by Anwita Biosciences and currently in Phase I for Lymphoma.

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Mantle Cell Lymphoma.

52

52

Pharmaceutical Technology

JANUARY 22, 2024

CD19 CAR-T Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

40

40

Pharmaceutical Technology

JUNE 7, 2023

Rituximab biosimilar is under clinical development by Celltrion and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

52

52

Pharmaceutical Technology

FEBRUARY 7, 2024

Acimtamig is under clinical development by Affimed and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL).

40

40

Pharmaceutical Technology

JULY 7, 2023

AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Follicular Lymphoma.

64

64

Pharmaceutical Technology

JANUARY 22, 2024

CD19 CAR-T Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Diffuse Large B-Cell Lymphoma.

40

40

Pharmaceutical Technology

FEBRUARY 7, 2024

STP-938 is under clinical development by Step Pharma and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).

Pharma 52

Pharma 52

Pharmaceutical Technology

JANUARY 22, 2024

CD19 CAR-T Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for B-Cell Non-Hodgkin Lymphoma.

40

40